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ratios	were	 used	 to	 rank	 compounds	 in	 order	 of	 intrinsic	 efficacy.	Adrenaline,	 no-
radrenaline,	and	phenylephrine	were	highly	efficacious	α1-	agonists	at	all	three	recep-
tor	subtypes.	A61603	was	the	most	selective	agonist	and	its	very	high	α1A-	selectivity	
was due to selective α1A-	affinity	(>660-	fold).	There	was	no	evidence	of	Gq-	calcium	
versus	ERK-	phosphorylation	biased	signaling	at	the	α1A,	α1B,	or	α1D-	adrenoceptors.	
There was little evidence for α1A	calcium	versus	cAMP	biased	signaling,	although	there	
were	suggestions	of	calcium	versus	cAMP	bias	the	α1B-	adrenoceptor.	Comparisons	of	
the rank order of ligand intrinsic efficacy suggest little evidence for selective intrinsic 
efficacy	between	the	compounds,	with	perhaps	the	exception	of	dobutamine	which	
may have some α1D-	selective	efficacy.	There	seems	plenty	of	scope	to	develop	affin-
ity selective and intrinsic efficacy selective drugs for the α1-	adrenoceptors	in	future.
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2 of 23  |     PROUDMAN AND BAKER




solely involves evaluating the affinity (ability of the ligand to bind to 
the	receptor).	However,	for	agonists,	there	are	two	properties	that	
need	to	be	evaluated:	affinity	and	efficacy	(ability	of	the	receptor-	
ligand	 complex	 to	 induce	 a	 response).1– 4	 A	 highly	 potent	 agonist	
could achieve this potency through high affinity or through high ef-





dependent	 factors	 include	 receptor	 number,	 receptor-	effector	
coupling	 efficiency,	 effector	 response	 measured,	 assay	 response	
window,	and	any	desensitization	that	occurs	within	the	timeframe	of	
the measurement. This makes direct comparisons of potency (EC50)	
impossible	 across	 systems.	 Ligand/receptor	 factors	 are	 the	 innate	
ability of a certain receptor– ligand complex to induce a response 
and depend upon the chemical interaction between ligand and re-
ceptor.	This,	termed	“intrinsic	efficacy”,	 is	a	measure	of	efficacy	at	
the molecular/single ligand– receptor level1,6 and is a more accurate 
measure of true ligand efficacy than either potency or maximal re-
sponse.7	A	good	way	to	compare	the	intrinsic	efficacy	of	ligands	is	to	
remove tissue/assay factors and measure responses from individual 
receptor subtypes for many agonists in parallel in a null background. 
This	allows	the	ligand's	intrinsic	efficacy	to	be	ranked	(e.g.	by	“effi-
cacy	 ratios”	KD/EC50
1,3,4,6)	 and	 thus	 compared	 across	different	 re-
ceptors. Previous studies using this have found that some agonists 
are highly selective purely because of a highly selective binding pro-
file,	and	not	because	of	any	intrinsic	efficacy	selectivity	(e.g.	salmet-
erol at β2-	adrenoceptors).8
The α1-	adrenoceptors	 (α1A,	 α1B,	 and	 α1D,	 Alexander	 et	 al.,	
2019/2020)	 are	Gq-	coupled	GPCRs	 expressed	 in	 a	wide	 range	 of	
tissues	 including	 blood	 vessels,	 heart,	 kidney,	 spleen,	 liver,	 brain,	
and lower urinary tract.9– 14 Whereas α-	adrenoceptor	 antagonists	




disorder e.g. guanfacine17,18),	 for	muscle	 spasm	and	spasticity	 (e.g.	
tizanidine19)	 but	 are	 probably	 most	 widely	 as	 over-	the-	counter	
nasal	 decongestants	 (e.g.	 oxymetazoline	 and	 xylometazoline20,21).	
Thus there are many structurally different α-	adrenoceptor	agonists	
with which to study agonist selectivity and determine how that is 
achieved.
In addition to α1-	adrenoceptor-	Gq-	PLC-	calcium	 signaling,	 the	
α1-	adrenoceptors	 have	 also	 been	 shown	 to	 stimulate	 other	 sig-
naling cascades.14,22,23 Some recent studies have suggested that 
biased signaling can occur via the α1A-	adrenoceptor.	 Isoprenaline	
was thought to have α1A-	cAMP	biased	signaling.24	Oxymetazoline	
was	initially	thought	to	have	ERK1/2-	phosphorylation	bias.25 It was 
later	confirmed	that	the	“biased”	responses	were	occurring	via	a	dif-
ferent	receptor	although	phenylephrine	and	methoxamine	ERK1/2-	
phosphorylation	 bias	 and	 A61603	 cAMP	 bias	 were	 proposed.26 
However	the	best	way	to	determine	whether	a	certain	ligand	is	in-
deed	an	outlier	inducing	biased-	signaling	is	to	examine	many	ligands	




was to examine the selectivity of a large range of agonists for the 
human α1A,	 α1B,	 and	 α1D-	adrenoceptors,	 with	 specific	 aims	 to	
identify whether agonists were selective due to selective affinity or 
selective	intrinsic	efficacy.	Additionally,	as	several	different	agonist	
responses	were	 examined,	 ligands	with	 bias	 toward	 one	 signaling	
cascade over another would also be identified.
2  |  MATERIAL S AND METHODS
2.1  |  Materials
3H-	prazosin,	 3H-	adenine,	 Microscint	 20,	 Ultima	 Gold	 XR	 scintil-




A	 list	 of	 the	 ligands	 studied	with	 the	 source	 and	 supplier	 code	 is	
given in Table S1.
2.2  |  Ligand selection
Commercially available ligands with known α-	adrenoceptor	agonist	
activity	 from	 the	 literature	were	 investigated.	 In	 addition,	 several	
ligands generally considered to be antagonists were investigated 
(taken	from	[28])	if	they	were	found	to	have	agonist	activity	at	one	or	
more α1-	adrenoceptors.	Brimonidine	and	UK14304	were	purchased	





2.3  |  Cell culture
CHO-	K1	 (RIDD:	 CVCL_0214)	 stably	 expressing	 the	 human	
α1A-	adrenoceptor,	 human	 α1B-	adrenoceptor,	 or	 human	 α1D-	
adrenoceptor	(full	length)	were	used.28
In	addition,	the	parental	CHO	cell	 line	without	any	transfected	
receptors was also used. Cells were grown in Dulbecco's modified 
Eagle's	 medium	 nutrient	 mix	 F12	 (DMEM/F12)	 containing	 10%	
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foetal	calf	serum	(FCS)	and	2	mM	L-	glutamine	in	a	37°C	humidified	
5%	CO2:	95%	air	atmosphere.
2.4  |  3H- prazosin whole- cell radioligand binding
Cells	 were	 grown	 to	 confluence	 in	 white-	sided	 96-	well	 view	
plates	 and	whole-	cell	 binding	 studies	were	 conducted	 as	 previ-
ously described28 in a total well volume of 200 µl per well. Cells 




sulosin 10 μM for α1A	and	α1B,	and	100	µM	for	α1D— see28 for 
full	 data	 and	 explanation)	 were	 determined	 in	 every	 plate.	 3H-	
prazosin	 concentrations	 were	 determined	 from	 the	 average	 of	
triplicate	50	µl	samples	of	each	3H-	prazosin	concentration	used	
and were in the range of 0.21 to 1.41 nM. KD values were cal-
culated from IC50	values	using	 the	Cheng-	Prusoff	equation	 (see	
below).
2.5  |  Intracellular free calcium mobilization
Cells	were	grown	to	confluence	in	black-	sided	96-	well	view	plates,	
and calcium measurements were made using a FlexStation 3 
at	 37°C.	 Cells	 were	 loaded	 for	 45	min	 at	 37°C	with	 Fluo-	4AM/
pluronic-	F127	 in	 sfm	 containing	 25	 mM	 probenecid.	 Cells	 were	
F I G U R E  1 Inhibition	of	3H-	prazosin	binding	to	whole	cells	to	CHO-	α1A	cells	(A–	C),	CHO-	α1B	cells	(D–	F),	or	CHO-	α1D	cells	(G–	I)	by	
adrenaline	(A,	D,	G),	A61603	(B,	E,	H)	or	dexmedetomidine	(C,	F,	I).	Bars	represent	total	3H-	prazosin	binding	and	non-	specific	binding,	
determined in the presence of 10 μM	tamsulosin	(CHO-	α1A	and	CHO-	α1B)	or	100	μM	tamsulosin	(CHO-	α1D).	The	concentration	of	3H-	
prazosin	was	(A)	0.34	nM,	(B)	0.20	nM,	(C)	0.22	nM,	(D)	0.42	nM,	(E)	0.44	nM,	(F)	0.22	nM,	(G)	0.58	nM,	(H)	0.58	nM	and	(I)	0.57	nM.	Data	
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washed twice with 2 × 200 μl	HEPES-	buffered	saline	 (HBS,	con-
taining 2 μM CaCl2).	80	µl	HBS	was	then	added	to	each	well	and	
the	plate	put	into	the	Flexstation.	Agonist	ligands	were	diluted	to	
five	times	final	concentration	of	HBS	 in	round	bottomed	96-	well	
compound plates and put in the Flexstation. The Flexstation robot-




well. The data were plotted as the maximum value obtained for 
calcium	mobilization	 over	 the	 basal	 value	 obtained	 for	 that	well	
before the addition of ligand.
2.6  |  ERK1/2- phosphorylation
Extracellular	 signal-	regulated	 kinases	 (ERK1/2)	 activation	 was	
measured	using	a	Surefire	Alphascreen	pERK1/2	kit	as	per	manu-
facturer's	 instructions.	 Cells	 were	 grown	 to	 confluence	 in	 clear-	
sided	 96-	well	 plates,	 then	 double	 serum	 starved	 by	washing	 the	
cells	 twice	with	100	µl	 sfm	before	 incubating	 in	 a	 further	 (third)	
100	µl	sfm	for	24	h	before	experimentation.	Agonists	in	20	µl	sfm	




lar pattern (with regards to EC50 value and proportion of the of the 
positive	 control	 response—	10	µM	PDBu);	 however,	 the	 response	
window	was	 greatest	 at	 2	 and	 5	min	 and	 thus	 all	 data	 reported	





settings.	 Basal	 and	maximum	 ERK1/2-	phosphorylation	 (as	 deter-
mined	by	10	µM	PDBu,	Phorbol	12,13-	dibutyrate)	was	measured	
in each plate.
2.7  |  3H- cAMP accumulation
Cells	 were	 grown	 to	 confluence	 in	 clear-	sided	 48-	well	 plates	 and	




10 µM forskolin were determined in every plate. Where used to ex-
amine	Gi-	coupled	responses,	basal	cAMP	was	augmented	by	10	μM 
forskolin	and	 inhibition	of	 this	 forskolin-	induced	response	was	ex-




2.8  |  Data analysis
All	pharmacological	data	were	plotted	using	Graphpad	Prism7.
2.9  |  Whole- cell binding
The affinity of 3H-	prazosin	 has	 previously	 been	 determined	 from	
saturation binding in these cell lines.28 The affinity of competing 
ligands	was	 determined	 from	 a	 one-	site	 sigmoidal	 response	 curve	
where the IC50	 is	the	concentration	required	to	 inhibit	50%	of	the	
specific binding of the 3H-	prazosin,	 A	 is	 the	 concentration	 of	 the	
competing	ligand	and	NS	is	the	non-	specific	binding	(Equation	1).
The affinity (KD	value)	of	the	competing	ligand	was	then	calcu-
lated from the IC50	using	the	Cheng-	Prusoff	equation	(Equation	2)	
where [3H-	prazosin]	is	the	concentration	of	3H-	prazosin	in	that	ex-
periment and KD 
3H-	prazosin	is	the	KD value of the radioligand.
2.10  |  Functional experiments
Agonist	 responses	 were	 usually	 best	 described	 by	 a	 one-	site	 sig-
moidal	concentration	response	curve	(Equation	3)	where	Emax is the 
maximum	response,	[A]	is	the	agonist	concentration	and	EC50 is the 
concentration	of	agonist	that	produces	50%	of	the	maximal	response








2.11  |  Efficacy ratios
Efficacy ratios were calculated by dividing the KD value by the EC50 
value for each ligand as per method of Furchgott.6
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2.12  |  Nomenclature of targets and ligands
Key	 protein	 targets	 and	 ligands	 in	 this	 article	 are	 hyperlinked	
to corresponding entries in http://www.guide topha rmaco logy.
org,	 the	 common	portal	 for	 data	 from	 the	 IUPHAR/BPS	Guide	 to	
PHARMACOLOGY	 (Harding	et	 al.,	 2018),	 and	are	permanently	 ar-
chived	in	the	Concise	Guide	to	PHARMACOLOGY	2019/20.29
3  |  RESULTS
3.1  |  Determination of ligand affinity from 3H- 
prazosin whole- cell binding
The affinity (KD)	 for	
3H-	prazosin	 has	 previously	 been	 determined	
in	these	cell	lines	as	0.71,	0.87,	and	1.90	nM	for	the	α1A,	α1B,	and	
α1D-	adrenoceptor,	 respectively,	 with	 receptor	 expression	 levels	
of	 1152fmol/mg	 protein,	 4350fmol/mg	 protein,	 and	 417fmol/mg	
protein,	respectively.28 The α1D-	adrenoceptor	is	the	full-	length	re-
ceptor and is associated with lower levels of expression than either 
α1A	 or	 α1B-	adrenoceptor	 expression,	 or	 an	 N-	terminal	 truncated	
α1D-	adrenoceptor.30– 33	As	expected	therefore,	the	window	of	spe-
cific	binding	was	smaller	 in	the	CHO-	α1D	cells	than	the	CHO-	α1A	
or	CHO-	α1B	 cells	 (Figure	 1).	 3H-	prazosin	whole-	cell	 binding	 stud-




lective agonist with an α1A-	adrenoceptor	selective	binding	affinity	
of	over	660-	fold	(Table	1,	Figure	1).
3.2  |  Free intracellular calcium mobilization
As	 all	 three	 α1-	adrenoceptors	 are	 primarily	 Gq-	coupled	 recep-
tors,	 intracellular	 calcium	 mobilization	 was	 studied.	 In	 CHO-	α1A	
cells,	adrenaline	stimulated	an	 increase	 in	 intracellular	calcium	(log	
EC50	=	−9.09)	that	was	58.9%	that	of	the	response	to	10	µM	iono-
mycin	 (Table	2,	Figure	2).	This	gave	adrenaline	an	efficacy	ratio	of	
4.00 making it the ligand with the greatest intrinsic efficacy at the 
α1A-	adrenoceptor	(Table	2).	A	similar	pattern	was	seen	in	CHO-	α1B 
and	CHO-	α1D	cells	(Tables	3	and	4,	respectively).
3.3  |  ERK1/2- phosphorylation
Adrenaline	 stimulated	 an	 increase	 in	 ERK1/2-	phosphorylation	 in	



























































































































































































































































































































































































































































































































































































































































































of	 the	 ligands	 (Table	2).	 In	CHO-	α1B	cells,	adrenaline	stimulated	a	
similar	bi-	phasic	ERK1/2-	phosphorylation	 response;	however,	only	
a	single	component	response	was	seen	in	CHO-	α1D cells (Tables 3 
and	4).
3.4  |  3H- cAMP accumulation
Adrenaline	stimulated	an	increase	in	3H-	cAMP	accumulation	in	CHO-	
α1A	cells	 (log	EC50	−5.63)	 that	was	164%	of	 the	 response	seen	to	
10	µM	forskolin	(Figure	4,	Table	2).	This	response	is	significantly	right-	
shifted	 when	 compared	 with	 the	 stimulatory	 adrenaline-	induced	
calcium	 mobilization	 and	 ERK1/2-	phosphorylation	 responses	 in	
these	 cells.	 To	 look	 for	 Gi-	mediated	 inhibition	 of	 cAMP,	 the	 abil-
ity	 of	 ligands	 to	 inhibit	 forskolin-	stimulated	 cAMP	was	 examined.	
In	 CHO-	α1A	 cells,	 adrenaline	 did	 not	 inhibit	 cAMP	 accumulation	





3.5  |  Responses in parent CHO cells without the 
transfected receptors
There	were	no	measurable	intracellular	calcium	mobilization	dose	
responses in response to any of the agonists in the parent (un-
transfected)	CHO	cells	(Table	S1).	A	few	compounds	had	a	higher	
than basal stimulation at the highest concentration only and are 
given	 in	Table	S1.	Oxymetazoline,	 xylometazoline,	 dihydroergot-
amine,	 lisuride,	 labetalol,	 and	 CGP	 12177	 stimulated	 ERK1/2-	
phosphorylation	 responses	 in	 the	 parent	 CHO	 cells	 (Table	 S1,	
F I G U R E  2 Intracellular	calcium	mobilization	in	CHO-	α1A	cells	(A–	C),	CHO-	α1B	cells	(D–	F),	or	CHO-	α1D	cells	(G–	I)	in	response	to	
adrenaline	(A,	D,	G),	A61603	(B,	E,	H)	or	dexmedetomidine	(C,	F,	I).	Bars	represent	basal	intracellular	calcium	release	and	that	in	response	to	




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































14 of 23  |     PROUDMAN AND BAKER
Figure	 S1).	 Oxymetazoline	 and	 xylometazoline	 responses	 had	
>10-	fold	higher	potency	 in	 the	CHO-	α1A	cells,	 suggesting	 these	
responses may be α1A-	receptor	 mediated.	 All	 other	 ERK1/2-	
phosphoryulation responses to these six ligands are similar in par-
ent	cells,	CHO-	α1A,	CHO-	α1B,and	CHO-	α1D cells and are likely 
non-	α1-	receptor	 mediated.	 Oxymetazoline	 and	 xylometazoline	
both	resulted	in	a	decrease	in	cAMP	accumulation	in	the	presence	
of	 forskolin	 in	 the	parent	 cells	 and	CHO-	α1D cells and for xylo-
metazoline	(less	efficacious	than	oxymetazoline)	in	the	CHO-	α1B. 
This	cAMP	 inhibition	was	also	not	α1-	mediated.	The	stimulatory	
cAMP	 responses	 to	 oxymetazoline	 and	 xylometazoline	 in	 CHO-	
α1A,	and	the	stimulatory	response	to	oxymetazoline	in	the	CHO-	
α1B cells are therefore likely α-	adrenoceptor	mediated.	These	six	
compounds	 are	 not	 included	 in	 the	 calcium	mobilization	 versus	
ERK1/2-	phosphorylation	correlation	plots	in	Figure	6A–	C.
3.6  |  Correlation plots
In	order	to	examine	for	any	evidence	of	bias	signaling,	the	log	EC50 
values	 for	 calcium	 mobilization	 were	 correlated	 with	 those	 for	
ERK1/2-	phosphorylation	(Figure	6A–	C).	This	suggests	little	evidence	




presence of forskolin as this has more ligands with measurable agonist 





same,	suggesting	 little	 loss	of	response	due	to	 ligand	degradation.5 
There	was	 also	 little	 evidence	 for	 calcium	versus	 cAMP	accumula-
tion bias at the α1A-	adrenoceptor.	There	was	however	some	scatter	
from the line of best fit for the α1B-	adrenoceptor,	suggesting	some	




Finally returning to a major aim of the study – to look for any evi-
dence of intrinsic efficacy selectivity – the efficacy ratios for calcium 
release were compared for α1A	and	α1B	 (Figure	6g)	 and	α1A	and	
α1D	(Figure	6h).	Here,	dobutamine	was	the	ligand	furthest	from	the	
line of best fit suggesting it has some α1D-	selective	efficacy	relative	
to that seen at the α1A	or	α1B-	adrenoceptors.
4  |  DISCUSSION
This study compared the binding affinity and functional responses 
of 62 compounds at the human α1A,	α1B,	α1D-	adrenoceptors.	α1A	







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































    |  17 of 23PROUDMAN AND BAKER
α1A	 and	 α1D-	adrenoceptors	 are	 important	 for	 vasoconstriction,	
the role of the α1B-	adrenoceptor	 (also	present	 in	blood	vessels)	 is	
less certain.10,14,36,37	Interestingly,	the	affinity	of	adrenaline	and	no-
radrenaline was substantially lower for the α1B-	adrenoceptor	than	
for α1A	or	α1D-	adrenoceptors.	 Adrenaline	 and	 noradrenaline	 had	
high	 intrinsic	 efficacy,	 with	 adrenaline	 being	 marginally	 higher	 at	
each receptor (in keeping with the slightly more potent adrenaline 
vs.	noradrenaline	responses	observed	by	[21,25,38]).	Phenylephrine	
(patented	1927,	in	clinical	use	since	193439)	and	noted	as	potent	by	
others,25,26 also had very high intrinsic efficacy.
A61603	was	the	most	selective	agonist	studied,	with	a	calcium	
release	and	ERK1/2-	phosphorylation	potency	(EC50	value)	in	CHO-	
α1A	cells	 in	 the	 sub-	nanomolar	 range,	 rather	 than	 the	micromolar	
range	of	the	CHO-	α1B	and	CHO-	α1D cells. This high α1A-	potency	




had α1A-	selective	 affinity,	 including	 PF3774076,	 oxymethazoline,	
lisuride,	xylometazoline,	and	dihydroergotamine.	No	compound	had	
α1B-	selectivity,	 and	 BMY7378	 (a	 known	 α1D-	antagonist31,41)	 was	
the only compound with α1D-	selective	affinity.
Phenylephrine,	 naphazoline,	 oxymetazoline,	 and	 xylometazoline	
are	 present	 in	 many	 non-	prescription	 nasal	 congestion	 treatments.	
They cause α-	agonist-	induced	vasoconstriction,	reducing	blood	flow	in	
nasal	mucosa,10 although there is still uncertainty about their clinical 
value.20,42 Even topical preparations have problems including rebound 
congestion	(first	reported	by	Feinberg	and	Friedlaender,43 and is still de-
bated,44,45)	and	predictable	systemic	α1A-	adrenoceptor	complications	
for example hypertension and headache.46,47 The α1A-	adrenoceptor	




(Tables	 1–	4),	 however,	 both	 oxymetazoline	 and	 xylometazoline	 had	
α1A-	adrenoceptor	selective	affinity.	A	degree	of	α1A	selective	affinity	
of these two compounds has also been previously reported.21,25,26,38,48
Although	 clear	 agonist	 responses	 were	 seen	with	 oxymetazo-
line	 for	 both	 calcium	 mobilization	 and	 ERK1/2-	phosphorylation	
in	 CHO-	α1A	 and	 CHO-	α1B	 cell	 lines;	 in	 CHO-	α1D	 cells,	 ERK1/2-	
phosphorylation responses were substantially greater than the α1D-	
calcium response raising the possibility of α1D-	biased-	signaling.	
Examination of other ligands reveals several compounds with sub-
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ation occurs in β1 and β3-	adrenoceptors,	where	 certain	 lower	 ef-
ficacy compounds activate a secondary agonist conformation49–	51 
involving the extracellular end of transmembrane 4.52	 A	 “low”	 af-








Overall,	 there	 was	 very	 close	 alignment	 between	 the	 cal-
cium	 mobilization	 and	 the	 ERK1/2-	phosphorylation	 responses	
(Figure	 6a–	c),	 suggesting	 no	 biased	 Gq/calcium	 versus	 ERK1/2-	
signaling	 in	CHO-	α1A,	CHO-	α1B,	or	CHO-	α1D cells. Copik et al.24 
examined α1A-	adrenoceptor	isoprenaline	responses	in	HEK	cells	in	
detail and concluded that although isoprenaline induced similar cal-
cium	and	ERK1/2-	phosphorylation	 responses,	 isoprenaline	did	not	
induce phospholipase C or inositol phosphate responses. They con-
cluded	that	their	calcium	response	was	a	non-	Gq-	coupled	event,	and	
thus	isoprenaline	was	an	ERK	versus	Gq-	biased	ligand.	Evans	et	al.25 
and da Silva et al.26 report phenylephrine and methoxamine as hav-
ing	 ERK	 versus	Gq-	calcium	bias.	 In	 our	 study,	 phenylephrine,	me-
thoxamine,	and	 isoprenaline	have	different	 intrinsic	efficacies,	but	
no	calcium	versus	ERK-	phosphorylation	bias.	It	 is	possible	that	the	
ERK1/2-	phosphorylation	 in	 our	 study	 could	 be	 downstream	 from	
the	calcium	response	(as	suggested	by	[22]).
Previous studies suggest that α1-	adrenoceptors	 stimulate	
cAMP.24,38,53,54	CHO-	α1A	 and	CHO-	α1B	 agonist	 cAMP	 responses	
were	seen	with	several	compounds,	although	not	in	the	α1D cells. In 
F I G U R E  3 ERK1/2-	phosphorylation	in	CHO-	α1A	cells	(A–	C),	CHO-	α1B	cells	(D–	F),	or	CHO-	α1D	cells	(G–	I)	in	response	to	adrenaline	(A,	
D,	G),	A61603	(B,	E,	H)	or	dexmedetomidine	(C,	F,	I).	Bars	represent	basal	ERK1/2-	phosphorylation	and	that	in	response	to	10	µM	PDBu	
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CHO-	α1A	cells,	cAMP	responses	required	much	higher	agonist	con-
centrations	than	that	required	for	calcium	release	(as	in	[24–	26,54]).	
This	 lower	potency	Gs-	coupling	 is	 similar	 to	 that	 seen	at	 the	ade-





α1A	 or	 CHO-	α1B	 cells,	 suggesting	 no	 evidence	 for	 Gi	 receptor	
coupling.	 In	 fact,	 forskolin	 further	 increased	 the	 cAMP	 stimula-
tory	 responses,	 in	 keeping	 with	 forskolin-	induced	 enhancement	
of	GPCR-	Gs-	adenylyl	cyclase	coupling	(proposed	by	[35]	and	[34]),	
and da Silva et al.26	who	were	not	able	to	measure	a	oxymetazoline-	
cAMP	 response,	 but	 observed	 an	 oxymetazloline	 response	 in	 the	
presence of 1 μM	forskolin.	In	CHO-	α1D	cells,	an	inhibitory	cAMP	
response	 was	 seen	 with	 oxymetazoline	 and	 xylometazoline,	 simi-
lar	 to	 that	 seen	 in	 parent	CHO	cells,	 suggesting	 that	 this	was	not	
α1D-	receptor	 mediated.	 Thus	 oxymetazoline	 and	 xylometazoline	
cause	non-	α1-	adrenoceptor-	mediated	 responses	 in	CHO	cells	 that	
decrease	cAMP	and	stimulate	significant	ERK-	phosphorylation,	very	
much	 in	 keeping	with	 the	 CHO	Gi-	coupled	 5HT-	1B	 receptor	 pro-
posed by da Silva et al.26	The	 stimulatory	 response	 seen	 in	CHO-	
α1A	and	CHO-	α1B	cells	is	likely	receptor-	mediated	due	to	the	higher	
level of transfected α-	adrenoceptors	in	these	cell	lines.
There	was	a	good	correlation	between	calcium	mobilization	and	
cAMP	stimulation	in	CHO-	α1A-	cells	suggesting	little	calcium	versus	





and	 dobutamine	 had	more	 potent	 cAMP	 responses	 than	 calcium.	
There may therefore be some bias signaling with respect to calcium 
and	cAMP	pathways	via	the	α1B-	adrenoceptor.
In α1A-	cells,	six	ligands	stimulated	biphasic	ERK1/2-	phosphorylation	
responses:	 an	 initial	 increase	 in	 phospho-	ERK1/2-	phosphorylation	
F I G U R E  4 3H-	cAMP	accumulation	in	CHO-	α1A	cells	(A–	C),	CHO-	α1B	cells	(D–	F),	or	CHO-	α1D	cells	(G–	I)	in	response	to	adrenaline	(A,	
D,	G),	A61603	(B,	E,	H),	or	dexmedetomidine	(C,	F,	I).	Bars	represent	basal	3H-	cAMP	accumulation	and	that	in	response	to	10	µM	forskolin	
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was	followed	by	a	decrease	at	higher	agonist	concentrations	(Figure	3).	
This appears to be an efficacy driven phenomena because these six 
ligands had the highest intrinsic efficacy as determined from the cal-
cium release assay. This phenomena was also seen with adrenaline 
and	noradrenaline	in	CHO-	α1B	cells,	but	not	in	CHO-	α1D cells (lower 
receptor	expression)	where	all	responses	were	smaller	relative	to	the	





Finally,	 the	 intrinsic	 efficacy	 of	 ligands	 was	 examined.	
Although	 direct	 EC50 comparisons are not possible across cell 
lines,	the	rank	order	of	intrinsic	efficacies	are	either	as	presented	
in	 Tables	 2–	4	 or	 pictorially	 from	 correlation	 plots	 (Figure	 6).	
There was a good correlation for the intrinsic efficacy of agonists 
at	these	receptors,	suggesting	little	intrinsic	activity	selectivity.	
The ligand with the most selective intrinsic efficacy was dobuta-
mine (ranked 4th in the α1D	table,	and	furthest	from	the	 line	of	
best	fit,	Figure	6).	Dobutamine	stimulated	a	response	with	similar	
affinity,	potency,	and	 intrinsic	efficacy	 to	 that	of	noradrenaline	
in	the	CHO-	α1D	cells,	but	despite	a	similar	affinity,	did	not	stim-
ulate	any	measurable	calcium	or	ERK1/2-	phosphorylation	CHO-	
α1B	 response	 and	 only	 a	 mid-	table	 response	 intrinsic	 efficacy	
response	in	the	CHO-	α1A	cells.	Dobutamine	has	previously	been	
shown to have affinity for α1-	adrenoceptors.56	However,	A61603	
apart,	given	the	 lack	of	selectivity	of	most	α1-	adrenoceptor	ag-
onists,	 there	 seems	 plenty	 of	 scope	 to	 develop	 both	 affinity-	
selective	 and	 intrinsic	 efficacy-	selective	 agonist	 drugs	 for	 the	
α1-	adrenoceptors	in	future.
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F I G U R E  5 3H-	cAMP	accumulation	in	the	presence	of	10	μM	forskolin	in	CHO-	α1A	cells	(A–	C),	CHO-	α1B	cells	(D–	F),	or	CHO-	α1D cells 
(G–	I)	induced	in	response	to	adrenaline	(A,	D,	G),	A61603	(B,	E,	H)	or	dexmedetomidine	(C,	F,	I).	Bars	represent	basal	3H-	cAMP	accumulation	
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F I G U R E  6 (A–	C)	Correlation	plots	of	log	EC50	determined	from	intracellular	calcium	mobilization	with	the	EC50	determined	from	ERK1/2-	
phosphorylation	in	(A)	CHO-	α1A	cells,	(B)	CHO-	α1B	cells,	and	(C)	CHO	α1D cells. The endogenous hormones adrenaline and noradrenaline 
are	represented	by	open	circles.	The	line	is	that	of	best	fit.	The	data	for	oxymetazoline,	xylometazoline,	dihydroergotamine,	lisuride,	
labetalol,	and	CGP	12177	are	not	included	in	these	plots	as	the	compounds	generated	agonist	ERK1/2-	phosphorylation	responses	in	non-	
transfected	cells	and	are	therefore	non-	α1-	mediated	responses.	(D–	F)	Correlation	plots	of	log	EC50 determined from intracellular calcium 
mobilization	with	the	EC50	determined	from	cAMP	accumulation	in	the	presence	of	forskolin	in	(D)	CHO-	α1A	cells,	(E)	CHO-	α1B	cells,	and	
(F)	CHO-	α1D	cells.	The	endogenous	hormones	adrenaline	and	noradrenaline	are	represented	by	open	circles.	The	line	is	that	of	best	fit.	(G–	I)	
Plots of efficacy ratio (KD/EC50)	for	(G)	α1A	versus	α1B,	(H)	α1A	versus	α1D,	and	(I)	α1B versus α1D	as	determined	from	whole-	cell	binding	
affinity	measurements	and	intracellular	calcium	mobilization.	The	endogenous	hormones	adrenaline	and	noradrenaline	are	represented	by	
open circles. The line is that of best fit and the slope is not 1 and does not necessarily go through the origin as this represents a function 
of	efficacy	(i.e.	differences	in	cell	line	which	include	receptor	number,	receptor-	effector	coupling	etc.).	Compounds	with	the	greatest	
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